Medication options are available to help manage the cognitive and behavioral symptoms of dementia and Alzheimer's disease.

Recent research suggests lecanemab may be less effective in females, raising important questions for future Alzheimer’s drug ...

Since becoming only the second Alzheimer's-modifying drug to gain American Federal Drug Administration approval in 2023, ...

Since becoming only the second Alzheimer's-modifying drug to gain American Federal Drug Administration approval in 2023, ...

This is the second time NICE made a decision not to approve these treatments for NHS use. Leqembi, marketed by Biogen and Eisai, was first rejected for NHS coverage in August 2024, while a negative ...

An appointment with Wendell Helveston, M.D., a neurologist in Hattiesburg, MS, led to a series of diagnostic tests, such as ...

For the first time, scientists say, they have evidence that using a biologic drug to remove sticky beta amyloid plaques from ...

Since becoming only the second Alzheimer's-modifying drug to gain American Federal Drug Administration approval in 2023, sales of lecanemab, known by its brand name Leqembi, have risen steadily ...

Eisai is responsible for the clinical development, applications for market approval and commercialization of Lecanemab for Alzheimer's disease. BioArctic has the right to commercialize Leqembi in ...

Researchers there were conducting part of a nationwide clinical trial of Leqembi, then known by its generic name, lecanemab.

The US regulator has granted accelerated approval to anti-amyloid therapy Leqembi (lecanemab) with a fairly broad label to treat patients in the mild cognitive impairment or mild dementia stage of ...